Introducing Vital®

Evolved tolerance nutrition

A whole new approach to nutrition therapy for supporting excellent GI tolerance and absorption

Video_icon
See the science behind improved tolerance nutrition.


With their advanced-technology ingredients, Vital® formulas are the most evolved way to reach nutrition goals for patients experiencing GI dysfunction:

Vital-Landing
RightCalloutTop RightCalloutBottom
  • Maldigestion
  • Impaired GI function
  • Malabsorption
  • Feeding intolerance

Advanced-technology ingredients

Technology has evolved over the past 20 years. Finally, nutrition therapy for GI intolerance has, too. As therapeutic, elemental nutrition for GI dysfunction, Vital® formulas offer an ingredient profile that includes:
  • Structured lipid
    • - Supports better absorption and tolerance compared with a simple physical mixture of MCT and LCT 1–4

  • 100% hydrolyzed, whey-dominant, peptide-based protein
    • - Promotes better absorption, tolerance, and maintenance of GI-tract integrity 5*
    • - Promotes faster gastric emptying (than casein-based peptide formulas) 6

  • NutraFlora® scFOS® prebiotic fiber
    • - Fermented to short-chain fatty acids, which help:
      • Maintain GI-tract integrity7,8
      • Manage diarrhea9

  • Elevated levels of antioxidants vitamins C and E
    • - Help reduce free-radical damage 10

Vital®—a more evolved level of nutrition therapy for patients with GI dysfunction


Vital AF 1.2 Cal™ Product Information
Vital®1.0 Cal Product Information
Vital® 1.5 Cal Product Information

*Compared to formulas containing only free amino acids or intact protein


For oral or tube feeding.
For supplemental or sole-source nutrition.
Not for IV use.
Use under medical supervision.
Gluten-free; suitable for lactose intolerance.
NutraFlora ® and scFOS ® are registered trademarks of GTC Nutrition.

References

  • Kenler AS, Swails WS, Driscoll DF, et al. Early enteral feeding in postsurgical cancer patients: fish oil structured lipid-based polymeric formula versus a standard polymeric formula.Ann Surg. 1996;223(3):316–333.
  • McKenna MC,Hubbard VS, Bieri JG. Linoleic acid absorption from lipid supplements in patients with cystic fibrosis with pancreatic insufficiency and in control subjects. J Pediatr Gastroenterol Nutr. 1985;4:45–51.
  • Tso P, Karlstad MD, Bistrian BR, DeMichele SJ. Intestinal digestion, absorption, and transport of structured triglycerides and cholesterol in rats. Am J Physiol. 1995;268 (Gastrointest Liver Physiol. 31):G568–G577.
  • Tso P, Lee T, DeMichele SJ. Lymphatic absorption of structured triglycerides vs. physical mix in a rat model of fat malabsorption. Am J Physiol. 1999;277 (Gastrointest Liver Physiol. 40):G333–G340.
  • Daniel H. Molecular and integrative physiology of intestinal peptide transport. Ann Rev Physiol. 2004;66:361–384.
  • Fried MD, Khoshoo V, Secker DJ, et al. Decrease in gastric emptying time and episodes of regurgitation in children with spastic quadriplegia fed a whey-based formula. J Pediatr. 1992;120:569–572.
  • Mitsuoka T, Hidaka H, Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Nahrung. 1987;31:427–436.
  • Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412.
  • Bowling TE, Raimundo AH, Grimble GK, Silk DB. Reversal by short-chain fatty acids of colonic fluid secretion by enteral feeding. Lancet. 1993;342:1266–1268.
  • Jacob RA, Burri BJ. Oxidative damage and defense. Am J Clin Nutr. 1996;985S–990S.